100% Quality Guarantee
PhD-Level Technical Support
Key Features

Durvalumab Biosimilar (PDL1) Antibody (HDBS0133)

SKU HDBS0133
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein PD-L1
Reactivity Human
Host Species Humanized
Isotype IgG1
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Durvalumab Biosimilar (PDL1) Antibody (HDBS0133)

The Durvalumab Biosimilar PD-L1 Antibody is a cutting-edge therapeutic antibody designed for research and potentially clinical applications. This biosimilar antibody targets the PD-L1 protein, a critical immune checkpoint molecule that helps cancer cells evade the immune system. By blocking PD-L1, Durvalumab enhances the immune response against cancer cells, making it a promising tool in cancer immunotherapy.This antibody is highly specific for PD-L1 and has been validated for use in various experimental settings, including flow cytometry, immunohistochemistry, and functional assays.

Its high affinity and potency make it an excellent choice for studying PD-L1 expression and function in cancer cells and tumor microenvironments.Overall, the Durvalumab Biosimilar Anti-PD-L1 Antibody is a valuable tool for researchers studying cancer immunology and exploring new strategies for cancer therapy. Its potential as a therapeutic agent in the treatment of various cancer types makes it a promising candidate for further development and investigation.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose